NCT03505515|Completed
Loading search results
Sponsor study identifier
observational
6,205
1 country
1
Study Start
December 7, 2017
Actual (reported)Primary Completion
September 11, 2020
Actual (reported)Study Completion
September 11, 2020
Actual (reported)The purpose of the study is to document real-world pattern of care, outcomes and health resource use for participants diagnosed with and receiving treatment for advanced Non-small cell lung cancer (NSCLC) and extensive disease Small cell lung cancer (SCLC) in China.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 11, 2020
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 7, 2017
Actual (reported)April 6, 2018
Actual (reported)April 23, 2018
Actual (reported)September 11, 2020
Actual (reported)September 11, 2020
Actual (reported)Proportion of participants receiving first-line systemic therapy
Proportion of patients receiving first-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy)
Approximately 36 months
Proportion of participants receiving second-line systemic therapy
Proportion of patients receiving second-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy)
Approximately 36 months
Proportion of participants receiving third-line systemic therapy
Proportion of patients receiving third-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy)
Approximately 36 months
Proportion of participants receiving fourth-line systemic therapy
Proportion of patients receiving fourth-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy)
Approximately 36 months
Distribution of first-line regimens
All chemotherapy, radiation and/or biologic drugs given to a patient during the first 28 days after initiation of treatment
Distribution of patient demographic data
At baseline
Distribution of disease characteristic data
At baseline
Distribution of Overall Survival from first observed diagnosis to death
At baseline
Distribution of Overall Survival from the initiation of first-line systemic anti-cancer therapy to death
At baseline
Distribution of Overall Survival from the initiation of second-line systemic anti-cancer therapy to death
At baseline
Participants with advanced/metastatic lung cancer (advanced NSCLC (IIIB/IV) and extensive disease SCLC) in China
Patients diagnosed with and receiving treatment for advanced NSCLC and extensive disease SCLC in China.
Local Institution
Shanghai, SHG, 200031, China
Qiu B, Li G, Luo F, Cai X, Wu L, Chen J, Hu Y, Tang Z, Yang S, He J. Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study. Transl Lung Cancer Res. 2020 Dec;9(6):2460-2468. doi: 10.21037/tlcr-20-1269.
Bristol-Myers Squibb
Bristol-Myers Squibb
6,205 participants (actual enrollment reported by the registry).
First Submitted
April 6, 2018
First Posted
April 23, 2018
Study Start
December 7, 2017
Actual (reported)Approximately 36 months
Distribution of subsequent regimens
All chemotherapy, radiation and/or biologic drugs given to a patient following first-line regimen
Approximately 36 months
Distribution of first-line treatment duration
Calculated by the difference between the treatment start date of the first observed drug in the regimen and the last observed date of the regimen
Approximately 36 months
Distribution of subsequent treatment duration
Calculated by the difference between the treatment start date of the first observed drug in the regimen and the last observed date of the regimen
Approximately 36 months
Distribution of first-line therapy completion rate
Completion of more than 4 cycles
Approximately 36 months
Distribution of subsequent therapy completion rate
Completion of more than 4 cycles
Approximately 36 months
Contact the study team to confirm eligibility.
Primary Completion
September 11, 2020
Actual (reported)Study Completion
September 11, 2020
Actual (reported)Last Updated
September 14, 2021
Record last verified: 2021-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: